Last reviewed · How we verify
CM512
CM512 is an investigational therapeutic targeting a specific molecular pathway in early clinical development by Keymed Biosciences.
At a glance
| Generic name | CM512 |
|---|---|
| Sponsor | Keymed Biosciences Co.Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
CM512 is currently in Phase 2 clinical trials. Without publicly disclosed mechanism details, the exact molecular target and therapeutic pathway remain proprietary to Keymed Biosciences. Further information would require access to clinical trial registries or company disclosures.
Approved indications
Common side effects
Key clinical trials
- A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. (PHASE2)
- Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis (PHASE1)
- Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) (PHASE2)
- Study of CM512 Injection in Subjects With Moderate-to-severe Asthma (PHASE2)
- Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1） (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM512 CI brief — competitive landscape report
- CM512 updates RSS · CI watch RSS
- Keymed Biosciences Co.Ltd portfolio CI